AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Ginkgo Bioworks Holdings reported steady business in Q3, with guidance indicating that this trend will continue until year-end. The company's cost-cutting efforts are reducing cash burn, but it needs to return to revenue growth to justify its valuation. Despite this, Ginkgo's scale and science-driven approach make it an attractive long-term investment.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet